Trial Profile
Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAPTURE
- 21 Feb 2023 Planned End Date changed from 1 Jan 2025 to 31 Jan 2025.
- 21 Feb 2023 Planned primary completion date changed from 1 Jan 2025 to 31 Jan 2025.
- 21 Feb 2023 Status changed from recruiting to active, no longer recruiting.